REFERENCES
- Hoorbakht H. Optic Neuritis, its Differential Diagnosis and Management. Open Ophthalmol J. 2012;6(1):65–72. doi:https://doi.org/10.2174/1874364101206010065.
- Martínez-Lapiscina EH, Fraga-Pumar E, Pastor X, et al. Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008–2012. J Neurol. 2014;261(4):759–767. doi:https://doi.org/10.1007/s00415-014-7266-2.
- Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol Chic IL 1960. 1991;109:(12):1673–1678. doi:https://doi.org/10.1001/archopht.1991.01080120057025.
- Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol Chic IL 1960. 1993;111(6):773–775. doi:https://doi.org/10.1001/archopht.1993.01090060061023.
- Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994;101(11):1771–1778. doi:https://doi.org/10.1016/s0161-6420(94)31103-1.
- Fernandes DB, Ramos R de IP, Falcochio C, Apóstolos-Pereira S, Callegaro D, Monteiro MLR. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2012;32(2):102–106. doi:https://doi.org/10.1097/WNO.0b013e31823a9ebc.
- Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain J Neurol. 2017;140(3):617–627. doi:https://doi.org/10.1093/brain/aww350.
- Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197–2200. doi:https://doi.org/10.1212/01.wnl.0000303817.82134.da.
- Merle H, Olindo S, Jeannin S, et al. Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis. Clin Ophthalmol Auckl NZ. 2013;7:1145–1153. doi:https://doi.org/10.2147/OPTH.S43894.
- Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007;114(4):810–815. doi:https://doi.org/10.1016/j.ophtha.2006.06.060.
- Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33(1):47–54. doi:https://doi.org/10.1097/WCO.0000000000000766.
- Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63(3):390–396. doi:https://doi.org/10.1001/archneur.63.3.390.
- Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165–1173. doi:https://doi.org/10.1212/WNL.0000000000001367.
- Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474–481. doi:https://doi.org/10.1212/WNL.0000000000000101.
- Kim S-M, Woodhall MR, Kim J-S, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e163. doi:https://doi.org/10.1212/NXI.0000000000000163.
- Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127–137. doi:https://doi.org/10.1136/jnnp-2017-316880.
- Jarius S, Kleiter I, Ruprecht K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016;13(1):281. doi:https://doi.org/10.1186/s12974-016-0719-z.
- Optic Neuritis Study Group. The clinical profile of optic neuritis. Arch Ophthalmol. 1991;109:1673–1678. doi:https://doi.org/10.1001/archopht.1991.01080120057025.
- Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol. 2016;79(3):437–447. doi:https://doi.org/10.1002/ana.24582.
- Loos J, Pfeuffer S, Pape K, et al. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. J Neurol. 2020;267(6):1632–1642. doi:https://doi.org/10.1007/s00415-020-09755-x.
- Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain J Neurol. 1991;114(Pt 6):2437–2450. doi:https://doi.org/10.1093/brain/114.6.2437.
- Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Contrast‐enhanced MRI in acute optic neuritis: relationship to visual performance. Brain. 2002;125(4):812–822. doi:https://doi.org/10.1093/brain/awf087.
- Rizzo JF, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109(9):1679–1684. doi:https://doi.org/10.1016/s0161-6420(02)01148-x.
- Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013;80(14):1330–1337. doi:https://doi.org/10.1212/WNL.0b013e3182887957.
- Huh S-Y, Min J-H, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler Houndmills Basingstoke Eng. 2014;20(6):695–704. doi:https://doi.org/10.1177/1352458513506953.
- Akaishi T, Nakashima I, Takeshita T, et al. Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol. 2016;299:152–157. doi:https://doi.org/10.1016/j.jneuroim.2016.09.007.
- Akaishi T, Nakashima I, Takeshita T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28–33. doi:https://doi.org/10.1016/j.jneuroim.2016.02.004.
- Akaishi T, Sato DK, Nakashima I, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016;87(4):446–448. doi:https://doi.org/10.1136/jnnp-2014-310206.
- Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018;195:8–15. doi:https://doi.org/10.1016/j.ajo.2018.07.020.
- Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858–e1869. doi:https://doi.org/10.1212/WNL.0000000000005560.
- Ducloyer J-B, Michel L, Wiertlewski S, Lebranchu P. Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein. Eur J Ophthalmol. 2019;29(2):257–261. doi:https://doi.org/10.1177/1120672118784797.
- Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298(1–2):158–162. doi:https://doi.org/10.1016/j.jns.2010.07.011.
- Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9(1):503. doi:https://doi.org/10.1186/1742-2094-9-14.
- Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. doi:https://doi.org/10.1186/s12974-016-0718-0.
- Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, Van Stavern GP. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2012;32(3):216–220. doi:https://doi.org/10.1097/WNO.0b013e318254c62d.
- Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276–283. doi:https://doi.org/10.1001/jamaneurol.2013.5857.
- Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses: therapy of NMO Attacks. Ann Neurol. 2016;79(2):206–216. doi:https://doi.org/10.1002/ana.24554.
- Lim Y-M, Pyun SY, Lim HT, Jeong IH, Kim -K-K. First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci. 2014;35(5):781–783. doi:https://doi.org/10.1007/s10072-014-1635-6.
- Mealy MA, Whetstone A, Orman G, Izbudak I, Calabresi PA, Levy M. Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci. 2015;355(1–2):59–63. doi:https://doi.org/10.1016/j.jns.2015.05.013.
- van Pelt ED, Wong YYM, Ketelslegers IA, Hamann D, Hintzen RQ. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol. 2016;23(3):580–587. doi:https://doi.org/10.1111/ene.12898.
- Pula JH, Kattah JC, Keung B, Wang H, Daily J. Longitudinally extensive optic neuritis in neuromyelitis optica spectrum disorder. J Neurol Sci. 2014;345(1–2):209–212. doi:https://doi.org/10.1016/j.jns.2014.07.049.
- Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler J. 2016;22(4):470–482. doi:https://doi.org/10.1177/1352458515593406.
- Salama S, Khan M, Levy M, Izbudak I. Radiological characteristics of Myelin Oligodendrocyte Glycoprotein antibody disease. Mult Scler Relat Disord. 2019;29:15–22. doi:https://doi.org/10.1016/j.msard.2019.01.021.
- Song H, Zhou H, Yang M, et al. Different Characteristics of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Seropositive Male Optic Neuritis in China. J Ophthalmol. 2019;2019:1–7. doi:https://doi.org/10.1155/2019/4015075.
- Storoni M, Davagnanam I, Radon M, Siddiqui A, Plant GT. Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis: A Novel Magnetic Resonance Imaging Scoring System. J Neuroophthalmol. 2013;33(2):123. doi:https://doi.org/10.1097/WNO.0b013e318283c3ed.
- Zhao G, Chen Q, Huang Y, et al. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. J Neurol. 2018;265(1):33–40. doi:https://doi.org/10.1007/s00415-017-8651-4.
- Zhao Y, Tan S, Chan TCY, et al. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102(10):1372–1377. doi:https://doi.org/10.1136/bjophthalmol-2017-311177.
- Burman J, Raininko R, Fagius J. Bilateral and recurrent optic neuritis in multiple sclerosis. Acta Neurol Scand. 2011;123(3):207–210. doi:https://doi.org/10.1111/j.1600-0404.2010.01388.x.
- Narayan R, Simpson A, Fritsche K, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66–72. doi:https://doi.org/10.1016/j.msard.2018.07.025.
- Li Y, Xie P, Lv F, et al. Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand. 2008;118(4):218–225. doi:https://doi.org/10.1111/j.1600-0404.2008.01012.x.
- Caron-Cantin M, Cestari DM, Fortin E. Clinical and radiologic approach to ‘typical’ versus antibody-related optic neuritis. Curr Opin Ophthalmol. 2019;30(6):412–417. doi:https://doi.org/10.1097/ICU.0000000000000614.
- Tajfirouz DA, Bhatti MT, Chen JJ. Clinical characteristics and treatment of MOG-IgG–associated optic neuritis. Curr Neurol Neurosci Rep. 2019;19(12):100. doi:https://doi.org/10.1007/s11910-019-1014-z.
- Peng Y, Liu L, Zheng Y, Qiao Z, Feng K, Wang J. Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis. Exp Ther Med. 2018. doi:https://doi.org/10.3892/etm.2018.6273.
- Son DY, Park K-A, Seok SS, Lee J-Y, Oh SY. Initial Pattern of Optic Nerve Enhancement in Korean Patients with Unilateral Optic Neuritis. Korean J Ophthalmol. 2017;31(1):71. doi:https://doi.org/10.3341/kjo.2017.31.1.71.
- Zhou L, Huang Y, Li H, et al. MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J Neuroimmunol. 2017;305:19–28. doi:https://doi.org/10.1016/j.jneuroim.2017.01.007.
- Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. doi:https://doi.org/10.1186/s12974-018-1144-2.
- Purvin V, Kawasaki A, Jacobson DM. Optic perineuritis: clinical and radiographic features. Arch Ophthalmol Chic IL 1960. 2001;119(9):1299–1306. doi:https://doi.org/10.1001/archopht.119.9.1299.
- Kidd DP, Burton BJ, Graham EM, Plant GT. Optic neuropathy associated with systemic sarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e270. doi:https://doi.org/10.1212/NXI.0000000000000270.
- Igarashi N, Sawamura H, Kaburaki T, Aihara M. Anti-Collapsing Response-Mediating Protein-5 Antibody-Positive Paraneoplastic Perioptic Neuritis without Typical Neurological Symptoms. Neuro Ophthalmol Aeolus Press. 2017;41(1):24–29. doi:https://doi.org/10.1080/01658107.2016.1241283.
- Miller DHF, Newton MRF, van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. 1988;38(2):175–179. doi:https://doi.org/10.1212/WNL.38.2.175.
- Dunker S, Wiegand W. Prognostic value of magnetic resonance imaging in monosymptomatic optic neuritis. Ophthalmology. 1996;103(11):1768–1773. doi:https://doi.org/10.1016/S0161-6420(96)30429-6.
- Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler Houndmills Basingstoke Eng. 2016;22(2):185–192. doi:https://doi.org/10.1177/1352458515581438.
- Plant GT, Sibtain NA, Thomas D. Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series. Mult Scler Int. 2011;2011:815068. doi:https://doi.org/10.1155/2011/815068.
- Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346–351. doi:https://doi.org/10.1136/jnnp-2017-316286.
- Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e504. doi:https://doi.org/10.1212/NXI.0000000000000504.
- Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572. doi:https://doi.org/10.1212/NXI.0000000000000572.
- Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1–16. doi:https://doi.org/10.1007/s00415-013-7169-7.
- Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e40. doi:https://doi.org/10.1212/NXI.0000000000000040.
- Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e131. doi:https://doi.org/10.1212/NXI.0000000000000131.
- Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128–3138. doi:https://doi.org/10.1093/brain/awx276.